SummaryRMgm-4595
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 30625318 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Matz JM, Matuschewski K |
Name Group/Department | Department of Molecular Parasitology, Institute of Biology |
Name Institute | Humboldt University |
City | Berlin |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4595 |
Principal name | adcl- |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation 'We also compared blood infection of transgenic parasites lacking the second pABA synthesis enzyme, ADCL, in mice receiving different diets. adcl- parasites (RMgm-4595) also depend on nutritional pABA, demonstrating that both enzymes, ADCS and ADCL, promote pABA biogenesis during blood infection. The ubiquitous expression of ADCL suggests additional functions, especially during mosquito stages. A previous study demonstrated a substantial secondary aminotransferase activity of Plasmodium falciparum ADCL, which was suggested as contributing to the detoxification of exogenous D-amino acids' See RMgm-4594 for a mutant lacking expression of ADCS. The following phenotype was described: 'Growth of asexual blood stages is normal in the presence of pABA in diet of mice. In milk-fed mice adcs- parasite propagation was severely impaired, whereas WT parasites displayed normal growth. Upon pABA supplementation via the drinking water, adcs- growth was fully restored, and mutant parasites grew indistinguishable from WT in milk-fed mice. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1322100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1458400 | ||||||||||||||||||||||||
Gene product | aminodeoxychorismate lyase | ||||||||||||||||||||||||
Gene product: Alternative name | ADCL | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | 539091 | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||
Additional remarks genetic modification | Constructs for endogenous tagging of ADCS and ADCL with mCherry-3xMyc were designed for single homologous integration. The sequences directly upstream of the stop codons were amplified from genomic DNA (1,053 and 1,663 bp, respectively) and inserted into the pBAT vector using HpaI in combination with EcoRI or NgoMIV. For the generation of the ADCS deletion construct, the 30 fragment of the gene was amplified from genomic DNA (1,185 bp) and cloned into the pBAT vector using the XhoI and KpnI restriction sites. Subsequently, the 50 fragment (508 bp) was amplified and cloned into the intermediate vectors using SacII in combination with HpaI. Prior to transfection, the ADCS knockout vector was linearized with SalI. Deletion of ADCL was performed with the respective NotI-digested PlasmoGEM vector. Internal restriction sites were used for linearization of the tagging vectors. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |